Enliven Therapeutics
Enliven Therapeutics
ELVN
NASDAQ
20.67
USD
1.87%
About
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach.
Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 118.4K |
| Three Month Average Volume | 5.4M |
| High Low | |
| Fifty-Two Week High | 27.6731 USD |
| Fifty-Two Week Low | 9.8 USD |
| Fifty-Two Week High Date | 29 Jul 2024 |
| Fifty-Two Week Low Date | 12 Dec 2023 |
| Price and Volume | |
| Current Price | 21.88 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -10.81% |
| Thirteen Week Relative Price Change | -9.42% |
| Twenty-Six Week Relative Price Change | 19.37% |
| Fifty-Two Week Relative Price Change | 11.79% |
| Year-to-Date Relative Price Change | 33.50% |
| Price Change | |
| One Day Price Change | -1.53% |
| Thirteen Week Price Change | -3.06% |
| Twenty-Six Week Price Change | 31.25% |
| Five Day Price Change | -4.87% |
| Fifty-Two Week Price Change | 40.08% |
| Year-to-Date Price Change | 58.09% |
| Month-to-Date Price Change | -17.06% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 5.94728 USD |
| Book Value Per Share (Most Recent Quarter) | 6.46406 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 5.94728 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 6.46406 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.25715 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.01383 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.93221 USD |
| Normalized (Last Fiscal Year) | -2.01383 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.01383 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.93221 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.01383 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.93221 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 6.12243 USD |
| Cash Per Share (Most Recent Quarter) | 6.62215 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.00539 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.91504 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.6763 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 33.22% |
| Tangible Book Value (5 Year) | 111.05% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -1.66% |
| EPS Change (Trailing Twelve Months) | -647.45% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -312,390,000 |
| Net Debt (Last Fiscal Year) | -253,148,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 58 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 4 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 4 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 10 |
| Current Ratio (Most Recent Quarter) | 14 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -61,418,000 |
| Free Cash Flow (Trailing Twelve Months) | -72,224,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -40.31% |
| Return on Assets (Trailing Twelve Months) | -26.91% |
| Return on Assets (5 Year) | -42.26% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -84.67% |
| Return on Equity (Trailing Twelve Months) | -28.37% |
| Return on Equity (5 Year) | -125.60% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -44.80% |
| Return on Investment (Trailing Twelve Months) | -28.35% |
| Return on Investment (5 Year) | -46.62% |